RxDoctor Payments Data

Jed Henry, MD

Urology · Mount Vernon, OHNPI 1851506661

Payments from drug & device makers

$11,902in general payments, 2019–2025

Across 427 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$4K
  • Olympus Winter & Ibe GmbH$1K
  • Johnson & Johnson$523
  • Neotract Inc.$522
  • AbbVie$450
  • Teleflex LLC$421
  • plus $5K from 42 others

What the payments were for

  • Consulting fees$1,58013%
  • Speaking & faculty fees$2,14118%
  • Travel & lodging$1461%
  • Food & beverage$7,15660%
  • Education$7346%
  • Gifts$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,902 in reported general payments places this provider in the 75th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$335,416
Medicare patients
974
Services billed
6,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron411$248,694
GemtesaVibegron158$115,928
Mirabegron ErMirabegron27$17,314
Alfuzosin Hcl ErAlfuzosin Hcl1,093$15,571
Tamsulosin Hcl541$8,059
Oxybutynin Chloride ErOxybutynin Chloride237$5,201
Finasteride367$4,034
Solifenacin Succinate60$3,524
NitrofurantoinNitrofurantoin Macrocrystal140$3,375
Trimethoprim100$3,346
Fesoterodine Fumarate ErFesoterodine Fumarate17$2,940
Potassium Citrate ErPotassium Citrate52$2,865
Testosterone Cypionate36$1,112
Dutasteride20$1,064
Tadalafil11$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$3,746$248,694411 claims
Sumitomo Pharma America, Inc.Gemtesa$391$115,928158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 485 urology providers in Ohio.

Other urology in Mount Vernon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →